EGFR and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, are orally administered small-molecule targeted therapeutics recommended as front-line therapy for a subset of advanced non-small cell lung cancer (NSCLC) patients who harbour EGFR-sensitizing somatic mutations [1].